AstraZeneca PLC (AZN)vsPharming Group NV (PHAR)
AZN
AstraZeneca PLC
$186.85
-0.22%
HEALTHCARE · Cap: $263.78B
PHAR
Pharming Group NV
$12.29
-0.08%
HEALTHCARE · Cap: $867.74M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 15767% more annual revenue ($61.37B vs $386.75M). AZN leads profitability with a 17.0% profit margin vs 6.3%. AZN trades at a lower P/E of 25.4x. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
PHAR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$186.85
$8.11 discount
Margin of Safety
-32.3%
Fair Value
$11.77
Current Price
$12.29
$0.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 33.9%
Earnings expanding 74.9% YoY
Reasonable price relative to book value
Revenue surging 20.8% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : PHAR
The strongest argument for PHAR centers on Operating Margin, EPS Growth, Price/Book. Revenue growth of 20.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : PHAR
The primary concerns for PHAR are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while PHAR is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
PHAR is growing revenue faster at 20.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 55/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Pharming Group NV
HEALTHCARE · BIOTECHNOLOGY · USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?